Table 3 Relationship between ZBTB9 expression level and clinicopathological variables in LIHC patients
Characteristic | Low expression of ZBTB9 (n = 187) No. (%) | High expression of ZBTB9 (n = 187) No. (%) | p. value |
|---|---|---|---|
T stage | Â | Â | 0.007 |
 T1 | 107 (57.22%) | 76 (40.64%) |  |
 T2 | 41 (21.93%) | 54 (28.88%) |  |
 T3 | 30 (16.04%) | 50 (26.74%) |  |
 T4 | 7 (3.74%) | 6 (3.21%) |  |
 Unknown | 2 (1.07%) | 1 (0.53%) |  |
N stage | Â | Â | 1.000 |
 N0 | 126 (67.38%) | 128 (68.45%) |  |
 N1 | 2 (1.07%) | 2 (1.07%) |  |
 Unknown | 59 (31.55%) | 57 (30.48%) |  |
M stage | Â | Â | 1.000 |
 M0 | 132 (70.59%) | 136 (72.73%) |  |
 M1 | 2 (1.07%) | 2 (1.07%) |  |
 Unknown | 59 (28.34%) | 49 (26.20%) |  |
PFI event | Â | Â | 0.301 |
 Alive | 101 (54.01%) | 90 (48.13%) |  |
 Dead | 86 (45.99%) | 97 (51.87%) |  |
DSS event |  |  |  < 0.001 |
 Alive | 158 (84.49%) | 129 (68.98%) |  |
 Dead | 26 (13.90%) | 53 (28.34%) |  |
 Unknown | 3 (1.60%) | 5 (2.67%) |  |
OS event |  |  |  < 0.001 |
 Alive | 140 (74.87%) | 104 (55.61%) |  |
 Dead | 47 (25.13%) | 83 (44.39%) |  |
Vascular invasion | Â | Â | 0.399 |
 No | 112 (59.89%) | 96 (51.34%) |  |
 Yes | 53 (28.34%) | 57 (30.48%) |  |
 Unknown | 22 (11.76%) | 34 (18.18%) |  |
Fibrosis ishak score | Â | Â | 0.341 |
 0 | 39 (20.86%) | 36 (19.25%) |  |
 1/2 | 16 (8.56%) | 15 (8.02%) |  |
 3/4 | 14 (7.49%) | 14 (7.49%) |  |
 5/6 | 52 (27.81%) | 29 (15.51%) |  |
 Unknown | 66 (35.29%) | 93 (49.73%) |  |
Child–Pugh grade |  |  | 0.138 |
 A | 116 (62.03%) | 103 (55.08%) |  |
 B | 15 (8.02%) | 6 (3.21%) |  |
 C | 1 (0.53%) | 0 (0.00%) |  |
 Unknown | 55 (29.41%) | 78 (41.71%) |  |
Prothrombin time | Â | Â | 0.849 |
 ≤ 4 | 108 (57.75%) | 100 (53.48%) |  |
 > 4 | 48 (25.67%) | 41 (21.93%) |  |
 Unknown | 31 (16.58%) | 46 (24.60%) |  |
Albumin(g/dl) | Â | Â | 1.000 |
 ≤ 3.5 | 36 (19.25%) | 33 (17.65%) |  |
 > 3.5 | 121 (64.71%) | 110 (58.82%) |  |
 Unknown | 30 (16.04%) | 44 (23.53%) |  |
AFP (ng/ml) | Â | Â | 0.036 |
 ≤ 400 | 120 (64.17%) | 95 (50.80%) |  |
 > 400 | 26 (13.90%) | 39 (20.86%) |  |
 Unknown | 41 (21.93%) | 53 (28.34%) |  |
Adjacent hepatic tissue inflammation | Â | Â | 0.696 |
 None | 66 (35.29%) | 52 (27.81%) |  |
 Mild | 51 (27.27%) | 50 (26.74%) |  |
 Severe | 9 (4.81%) | 9 (4.81%) |  |
 Unknown | 61 (32.62%) | 76 (40.64%) |  |
Histologic grade | Â | Â | 0.198 |
 G1 | 33 (17.65%) | 22 (11.76%) |  |
 G2 | 82 (43.85%) | 96 (51.34%) |  |
 G3 | 61 (32.62%) | 63 (33.69%) |  |
 G4 | 8 (4.28%) | 4(2.14%) |  |
 Unknown | 3 (1.60%) | 2 (1.07%) |  |
Residual tumor | Â | Â | 0.179 |
 R0 | 167 (89.30%) | 160 (85.56%) |  |
 R1 | 6 (3.21%) | 11 (5.88%) |  |
 R2 | 0 (0.00%) | 1 (0.53%) |  |
 Unknown | 14 (7.49%) | 15 (8.02%) |  |
BMI | Â | Â | 0.168 |
 ≤ 25 | 83 (44.39%) | 94 (50.27%) |  |
 > 25 | 88 (47.06%) | 72 (38.50%) |  |
Unknown | 16 (8.56%) | 21 (11.23%) | Â |
Heigh | Â | Â | 0.062 |
 ≤ 170 | 93 (49.73%) | 108 (57.75%) |  |
 > 170 | 80 (42.78%) | 60 (32.09%) |  |
 Unknown | 14 (7.49%) | 19 (10.16%) |  |
Weight | Â | Â | 0.194 |
 ≤ 70 | 86 (45.99%) | 98 (52.41%) |  |
 > 70 | 88 (47.06%) | 74 (39.57%) |  |
Unknown | 13 (6.95%) | 15 (8.02%) | Â |
Age | Â | Â | 0.961 |
 ≤ 60 | 89 (47.59%) | 88 (47.06%) |  |
 > 60 | 97 (51.87%) | 99 (52.94%) |  |
 Unknown | 1 (0.53%) | 0 (0.00%) |  |
Race | Â | Â | 0.571 |
 Asian | 75 (40.11%) | 85 (45.45%) |  |
 Black or African. American | 9 (4.81%) | 8 (4.28%) |  |
 White | 97 (51.87%) | 88 (47.06%) |  |
 Unknown | 81(43.32%) | 91 (48.66%) |  |
Gender | Â | Â | 0.269 |
 Female | 55 (29.41%) | 66 (35.29%) |  |
 Male | 132 (70.59%) | 121 (64.71%) |  |
Tumor status | Â | Â | 0.010 |
 Tumor free | 115 (61.50%) | 87 (46.52%) |  |
 With tumor | 65 (34.76%) | 88 (47.06%) |  |
 Unknown | 7 (3.74%) | 12 (6.42%) |  |
Pathologic stage | Â | Â | 0.024 |
 I | 102 (54.55%) | 71 (37.97%) |  |
 II | 38 (20.32%) | 49 (26.20%) |  |
 III | 36 (19.25%) | 49 (26.20%) |  |
 IV | 3 (1.60%) | 2 (1.07%) |  |
 Unknown | 8 (4.28%) | 16 (8.56%) |  |
Age, median (IQR) | 61 (54–68, 32.62%) | 61 (51–70, 32.62%) | 0.944 |
Unknown | 126 (67.38%) | 126 (67.38%) | Â |